Cart
sales@molnova.com
Lumretuzumab
CAS No. 1448327-63-6
Lumretuzumab( —— )
Catalog No. M36732 CAS No. 1448327-63-6
Lumretuzumab (RG-7116) is a humanized anti-HER3 monoclonal antibody with antitumor activity for the study of advanced HER3-positive solid tumors and breast cancer.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 660 | In Stock |
|
| 10MG | 1036 | In Stock |
|
| 25MG | 1568 | In Stock |
|
| 50MG | 2065 | In Stock |
|
| 100MG | Get Quote | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameLumretuzumab
-
NoteResearch use only, not for human use.
-
Brief DescriptionLumretuzumab (RG-7116) is a humanized anti-HER3 monoclonal antibody with antitumor activity for the study of advanced HER3-positive solid tumors and breast cancer.
-
DescriptionLumretuzumab (Anti-Human ERBB3 Recombinant Antibody) is a humanized anti-HER3 (ERBB3) monoclonal antibody that can be used for the research of cancer.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayAngiogenesis
-
TargetEGFR
-
RecptorEGFR
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number1448327-63-6
-
Formula Weight
-
Molecular Formula——
-
Purity>98% (HPLC)
-
Solubility——
-
SMILES——
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Schneeweiss A, et al. Phase Ib study evaluating safety and clinical activity of the anti-HER3 antibody lumretuzumab combined with the anti-HER2 antibody pertuzumab and paclitaxel in HER3-positive, HER2-low metastatic breast cancer. Invest New Drugs. 2018 Oct;36(5):848-859.?
molnova catalog
related products
-
Canertinib dihydroch...
A potent, irreversible, orally available pan-ErbB inhibitor for EGFR and ErbB2 with IC50 of 7.5 nM and 9.0 nM in autophosphorylation assay.
-
HS-10296
Hs-10296 is an inhibitor of EGFR activation mutation and tolerant mutation of EGFR T790M which has only limited activity against wild-type EGFR.
-
Poziotinib hydrochlo...
Poziotinib hydrochloride irreversibly inhibits EGFR (HER1 or ErbB1), including EGFR mutants, HER2, and HER4, thereby inhibiting the proliferation of tumor cells that overexpress these receptors.?It is an orally bioavailable, quinazoline-based pan epidermal growth factor receptor (EGFR or HER) inhibitor with potential antineoplastic activity.?
